LY2452473 + Tadalafil + LY900010
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
Jul 1, 2011 → Sep 1, 2011
NCT ID
NCT01401543About LY2452473 + Tadalafil + LY900010
LY2452473 + Tadalafil + LY900010 is a phase 1 stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01401543. Target conditions include Erectile Dysfunction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01401543 | Phase 1 | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo | Yuhan | Phase 2 | 52 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 85 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 41 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil | Eli Lilly | Phase 3 | 77 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 52 |
| Tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + placebo | Eli Lilly | Approved | 85 |
| Tadalafil + Sildenafil Citrate | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 85 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 77 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor) | Johnson & Johnson | Phase 3 | 77 |